1-Dimethylamino-3-(α-naphthyl)-propan | 25913-62-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-Dimethylamino-3-(α-naphthyl)-propan
• 英文别名: N.N-Dimethyl-3-(1-naphthyl)propylamin；1-Naphthalenepropanamine, N,N-dimethyl-；N,N-dimethyl-3-naphthalen-1-ylpropan-1-amine
• CAS: 25913-62-6
• 化学式: C₁₅H₁₉N
• 分子量: 213.323
• InChiKey: RKRSLNMXXPUVPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Exciplexes
  申请人：——

  公开号：US20030108892A1

  公开（公告）日：2003-06-12

  Compounds capable of forming an intramolecular exciplex on photoirradiation of the compound in water comprise two exciplex forming partners, one being a donor moiety and the other an acceptor moiety, each having at least one aromatic nucleus and being connected by a saturated aliphatic chain having the flexibility to allow said partners to come into exciplex forming relationship. The compounds may be used as labels for oligonucleotides. Certain of the compounds display pH sensitive emission.

  在水中光照条件下能够形成分子内激发态络合物的化合物包括两个激发态络合物形成合作伙伴，一个是给体基团，另一个是受体基团，每个基团至少具有一个芳香环，并通过具有足够柔韧性的饱和脂肪链连接，使这些合作伙伴能够形成激发态络合物关系。这些化合物可用作寡核苷酸的标记。其中一些化合物显示出pH敏感的发射特性。
• EXCIPLEXES
  申请人：THE VICTORIA UNIVERSITY OF MANCHESTER

  公开号：EP1242360A2

  公开（公告）日：2002-09-25
• [EN] EXCIPLEXES<br/>[FR] EXCIPLEXES
  申请人：UNIV MANCHESTER

  公开号：WO2001046121A2

  公开（公告）日：2001-06-28

  Compounds capable of forming an intramolecular exciplex on photoirradiation of the compound in water comprise two exciplex forming partners, one being a donor moiety and the other an acceptor moiety, each having at least one aromatic nucleus and being connected by a saturated aliphatic chain having the flexibility to allow said partners to come into exciplex forming relationship. The compounds may be used as labels for oligonucleotides. Certain of the compounds display pH sensitive emission.
• [EN] COMPOUNDS WITH ANTI-EMETIC EFFECT<br/>[FR] COMPOSÉS À EFFET ANTIÉMÉTIQUE
  申请人：SANTHERA PHARMACEUTICALS CH

  公开号：WO2009080351A1

  公开（公告）日：2009-07-02

  The present invention relates to the use of Melanocortin-4 receptor antagonists in the treatment of emesis and nausea.